Cancer

22 February 2007

Cancer drug fights tumors

The cancer drug Avastin appears able to slow the growth of the most common and deadly form of brain cancer -gliomas - and extend patient survival.

0
The cancer drug Avastin (bevacizumab) appears able to slow the growth of the most common and deadly form of brain cancer -- gliomas -- and extend patient survival, according to a pilot study conducted at Duke University Medical Center in Durham, N.C.

Avastin is designed to shrink cancerous tumors by cutting off their blood supply. Currently, the drug is used to treat lung and colorectal cancers. This is the first time that Avastin has been tested as a treatment for malignant brain tumors.

Researchers used Avastin in conjunction with a standard chemotherapy drug to treat 32 people with stage III or stage IV recurrent gliomas.

After 12 weeks, tumors shrank by at least 50 percent in 63 percent of the patients. After six months, 38 percent of the patients were progression-free (their tumors had not grown).

The combination of Avastin and chemotherapy halted tumor growth up to twice as long as comparative therapies, the study authors said.

The findings are published in the Feb. 20 issue of the journal Clinical Cancer Research. The study received funding from Genentech, the maker of Avastin.

"These results are exciting because of the possible implications for a patient population that currently has the poorest possible prognosis going into treatment, those with malignant brain tumors that have recurred after initial treatment," lead researcher Dr. James Vredenburgh, a brain cancer specialist at Duke's Preston Robert Tisch Brain Tumor Center, said in a prepared statement.

Duke is currently participating in a large, multi-center study of Avastin to confirm the results of this pilot study.

(Health Scout News)

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit cansa.org.za.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules